Related Experiment Videos
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
Suoping Zhai1, Adrian M Senderowicz, Edward A Sausville
1Center for Cancer Research, National Cancer Institute, Building 10 Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Objective:
To review preclinical and clinical information on flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), tested as an antitumor agent.
Data Sources:
Primary and review articles were identified by MEDLINE search (1990-June 2001). Abstracts from recent meetings were also used as source materials.
Data Extraction:
Flavopiridol was reviewed with regard to its mechanisms, preclinical and clinical results, pharmacokinetics, and metabolism.
Data Synthesis:
Flavopiridol is an inhibitor of several CDKs and displays unique anticancer properties. In addition to direct CDK inhibition, flavopiridol also exhibited other features such as inducing apoptosis in many cancer cell lines, decreasing cyclin D1 concentration, and inhibiting angiogenesis. Preclinical xenograft models showed significant antitumor activity for flavopiridol. The regimen using 72-hour continuous infusion every 2 weeks has been most extensively applied in clinical trials, with a 1-hour infusion currently being explored to achieve higher peak concentrations. Several Phase I and II trials have been reported, with some evidence of antitumor activity noted. Further Phase I and II trials using flavopiridol as a single agent and in combination with standard chemotherapeutic regimens and various tumor types are ongoing.
Conclusions:
Flavopiridol is the first CDK inhibitor to enter clinical trials. Several Phase I and Phase II clinical trials with different regimens (72-h or 1-h infusion) have been completed. Initial clinical trials have been intriguing, but many questions remain: What is the best regimen (< or =72-h infusion)? Does optimal future development of this drug depend on the combination with other chemotherapy? What is the best combination of flavopiridol with other chemotherapy?
Insights
Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, shows anticancer properties and has entered early clinical trials. Further research is needed to determine optimal dosing and combination therapies for this novel antitumor agent.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Flavopiridol is an inhibitor of cyclin-dependent kinases (CDKs).
- CDKs play a crucial role in cell cycle regulation and cancer progression.
- Flavopiridol has been investigated as a potential antitumor agent.
Purpose of the Study:
- To review preclinical and clinical data on flavopiridol.
- To assess its efficacy as an antitumor agent.
- To understand its mechanisms, pharmacokinetics, and metabolism.
Main Methods:
- Literature search of MEDLINE (1990-June 2001) and meeting abstracts.
- Review of preclinical studies, including xenograft models.
- Analysis of data from Phase I and II clinical trials.
Main Results:
- Flavopiridol inhibits multiple CDKs and exhibits anticancer properties, including apoptosis induction and anti-angiogenesis.
- Preclinical models demonstrated significant antitumor activity.
- Clinical trials with continuous 72-hour infusions and shorter 1-hour infusions showed some evidence of antitumor activity.
Conclusions:
- Flavopiridol is the first CDK inhibitor to enter clinical trials.
- Ongoing trials are evaluating different regimens and combinations with chemotherapy.
- Optimal treatment strategies, including best regimen and combination therapy, require further investigation.